[Experience with the use of 9,3"-diacetylmidecamycin dry syrup in pediatrics].
Some studies were carried out on the use of 9,3"-diacetylmidecamycin (MOM) dry syrup, a new macrolide antibiotic preparation, in the treatment of children. The results are summarized below. 1) A single oral dose of 10 mg/kg of the MOM dry syrup was administered to 1 child at 2 hours after a meal. The peak concentration of the antibiotic in the blood was 0.88 micrograms/ml and occurred at 1 hour after administration. At 2 hours the concentration had fallen to 0.59 microgram/ml, and after 4 hours the blood level was already below the minimum detectable concentration (0.5 microgram/ml). During the first 6 hours after the administration, 6.7% of the MOM was recovered in the urine. 2) The MOM dry syrup was orally administered to 4 pneumonia patients (including 2 cases of mycoplasmal pneumonia) for 7 days at a daily dosage of 15.2--20.5 mg/kg (divided into 3 equal doses). The therapeutic results were excellent in 2 cases, good in 2 cases and poor in none. 3) No side effects such as exanthema were observed to occur. In 1 case only, there was a mild and temporary elevation in the laboratory test values for total bilirubin, GOT and GTP. 4) All 4 of the pneumonia patients found the MOM dry syrup to be easy to ingest. The taste and odor of this antibiotic preparation were judged to be sufficiently palatable to permit convenient use in the treatment of children.
D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D004304:Dosage Forms; D004341:Drug Evaluation; D006801:Humans; D007933:Leucomycins / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D015644:Miocamycin; D011014:Pneumonia / Q000188:drug therapy*; D011019:Pneumonia, Mycoplasma / Q000188:drug therapy
D004304:Dosage Forms; D007933:Leucomycins; D015644:Miocamycin